Hemispherian

small molecule drugs, called GLIX, which target the TET2 enzyme and activate the DNA damage response resulting in cancer cell death. In March 2021, the company was granted its first patent from the United Kingdom Intellectual Property Office for the use of compounds from the GLIX drugs. 

Its lead drug candidate, GLIX1, was in late-stage preclinical development to treat glioblastoma (cancer of the central nervous system), as of July 2023. Additionally, its other drug candidate, GLIX5, was at the proof-of-concept stage as a target for a broader range of cancer and the company had two targets in the early discovery stage. The company was also developing a companion diagnostic tool that helps identify potential candidates who would benefit from GLIX1. 

Funding and Financials

In November 2022, the company raised USD 2.9 million (NOK 30 million) in its first tranche of the Series A1 funding round, which was led by Meneldor. The raised funds were used to drive the company’s existing drug development initiatives, enhance its preclinical pipeline, and advance the development of its drug candidates, GLIX1 and GLIX5.